TP53 and neoplasm: Additionally, there is evidence suggesting that combination therapies may activate tumor suppressor pathways such as p53 and checkpoint kinases (Chk1/Chk2), triggering irreversible cell cycle arrest and caspase-mediated apoptosis (34).